---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108280"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:48:29.968254+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# FibroGen amends debt agreement, reduces minimum cash requirement from $18.75M to $15M

## Summary
- Fourth Amendment to Financing Agreement with Morgan Stanley Tactical Value lenders executed August 12, 2025.
- Minimum qualified cash balance reduced from $18.75 million to $15.0 million effective immediately.
- Prior amendments dated May 8, June 5, and July 14, 2025 indicate ongoing covenant adjustments.

## SEC filing metadata
- accession: 0000950170-25-108280
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/0000950170-25-108280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/fgen-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108280
- JSON: https://secwatch.observer/filing/0000950170-25-108280.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.